Catabasis pharmaceuticals inc (CATB)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Operating activities
Net loss

-7,952

-6,610

-6,514

-7,131

-6,038

-6,060

-5,679

-6,479

-7,652

-5,497

-7,017

-6,974

-7,876

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,418

-

-8,484

-8,040

-6,500

Reconciliation of net loss to net cash used in operating activities:
Non-cash items

-341

-

-

-

-416

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of discount/premium on investment securities

2

-

-

-

7

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

8

6

43

62

67

72

77

88

95

105

103

92

72

37

41

52

Stock-based compensation expense

-

-

-

-

-

431

416

445

479

506

515

481

505

585

510

517

548

515

488

354

301

Accretion of discount/premium on investment securities

-

-

-

-

-

-

-

-

-

0

-1

0

-25

-41

-30

-39

-38

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-1

5

13

20

27

34

44

50

59

65

74

79

84

86

85

38

Services received in non-monetary exchange

8

15

8

4

6

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in assets and liabilities:
Prepaid expenses and other current assets

-669

618

1,127

-102

-354

57

761

-436

-205

-5

207

-128

19

82

7

102

38

213

63

-20

194

Other assets

-

-

0

0

25

-

-

-

-

-

-

-

-

-

-

-

2

-

-

-

-

Right-of-use asset-operating

51

-60

-27

-21

12

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-501

-893

842

-208

48

388

676

-744

342

-429

-853

1,118

-468

-101

-32

-20

230

-423

-30

728

-79

Accrued expenses

393

82

-31

1,057

-1,313

129

-280

824

-277

-312

49

-498

-454

166

874

41

-663

842

123

826

-837

Deferred rent

-

-

-

-

-

-

-

-

-

-4

-8

-26

44

34

0

-13

-13

-14

14

-9

-9

Other liabilities

-

-13

-5

3

-54

-31

-8

3

2

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-6,989

-7,770

-6,474

-5,738

-6,587

-5,269

-5,775

-5,602

-6,819

-5,637

-7,414

-5,680

-8,105

-

-

-

-

-

-

-

-

Investing activities
Purchases of short-term investments

42,777

31,842

34,849

41,491

47,015

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sales and maturities of short-term investments

27,345

28,350

48,500

45,000

29,277

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,147

-

-7,827

-5,995

-7,228

Purchases of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

4,042

9,386

0

32,111

-

-

-

-

Sales and maturities of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

0

14,910

9,872

7,081

10,171

3,332

-

-

-

-

Purchases of property and equipment

-

-

-

-

-

-

-

-

-

0

18

30

9

23

48

98

290

361

25

10

25

Net cash used in investing activities

-15,432

-3,504

13,651

3,509

-17,738

-

-

-

-

0

-18

0

14,901

-

-

-

-

-

-

-

-

Financing activities
Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-29,069

-

-25

-10

-25

Proceeds from public offerings, net of issuance costs

24,564

0

0

-130

18,635

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

12,331

Proceeds from at-the-market offering, net of issuance costs

1,060

3,772

974

270

2,045

-60

0

0

8,313

1,126

609

4,086

2,215

-

-

-

-

-

-

-

-

Proceeds from exercise of common stock options and warrants

-

-

-

-

-

-

-

-

-

0

0

2

21

-

-

-

-

-

-

-

-

Proceeds from exercise of common stock options and warrants

-

-

-

-

3

-

-

-

-

-

-

-

-

-

-

24

87

-

0

0

51

Proceeds from borrowing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

5,000

Payments on borrowing

-

-

-

-

-

348

833

834

833

833

833

834

833

833

834

833

833

-

-

-

-

Deferred initial public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

487

Debt issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

7

Net cash provided by financing activities

25,624

3,772

973

192

20,683

-407

-1,273

38,495

7,480

293

-224

3,254

1,403

-

-

-

-

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

3,203

-7,502

8,150

-2,037

-3,642

-4,582

-30,055

32,901

661

-5,344

-7,656

-2,426

8,199

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-746

-

-987

63,250

16,888

Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,868

2,186

460

-38,962

-9,929

-8,839

57,245

9,635

Supplemental disclosure of cash flow information
Cash paid for interest

-

-

-

-

-

0

11

26

42

58

74

91

104

-

-

-

-

-

-

-

-

Non-cash investing activities:
Fixed asset purchases included in accounts payable

9

-

-

-

-

-

-

-

-

-

-

-

5

-

-

-47

68

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

163

-

246

160

94

Non-cash financing activities
Public offering issuance costs included in current liabilities

5

-

-

-

130

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrants for the purchase of series B preferred stock issued in conjunction with credit facility

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-3

3

107

Public offering issuance costs included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-524

-938

495

475